Course InformationTherapautic Area: Cardiology
Credit(s): 0.50 AMA PRA Category 1 Credit™
Activity Dates: September 5, 2018 - September 4th, 2019
In this module of a Four-Part Expert Interview Series, Dr. James A. Underberg, along with Dr Christopher P. Cannon, course chair, will identify barriers to caring for dyslipidemia patients. There barriers will include financial and other patient-related obstacles. This discussion will incorporate strategies to improve access to PCSK9 inhibitors, in turn leading to improved patient outcomes.
Cardiologists, internists, and other healthcare professionals involved in the management of patients with dyslipidemia.
1. Utilize recent guidelines and recommendations when making treatment decisions for patients
2. Recognize potential financial and treatment access barriers that may impact standard of care
Christopher P. Cannon, MD
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
James A. Underberg, MD, MS
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Christopher P. Cannon, MD||Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Janssen Global Services, LLC; Kowa Company, Ltd.; Merck & Co.; Pfizer Inc.; Regeneron; SanofiGrant/Research Support: Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co.|
|James A. Underberg, MD, MS||Consultant/Advisor: Aegerion Pharmaceuticals Inc; Akcea Therapeutics; Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc.; Invitae Corporation; Regeneron; SanofiGrant/Research Support: Aegerion Pharmaceuticals Inc; Pfizer Inc.Speakers Bureau: Akcea Therapeutics; Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc.; Regeneron; Sanofi|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CME inquiries or special needs, please contact email@example.com.